By leveraging proteomics technology, BERTIS Inc. has developed a unique AI-based diagnostic platform that enables the accurate and early detection of diseases such as cancer and cardiac diseases. Their platform uses proteomics-based molecular diagnostics to discover disease-related biomarkers, allowing medical practitioners to effectively treat patients in the early stages of the disease. BERTIS Inc. has grown into a global representative proteomics company by collaborating with experts in various fields, including physicians, chemists, biologists, and engineers.